S-1 monotherapy in patients with advanced biliary tract cancer
Sasaki T et al. - In a trial to evaluate the efficacy and safety of single-agent S-1 in pts with advanced biliary tract cancer, it was reported that S-1 monotherapy is a feasible and moderately efficacious treatment for advanced biliary tract cancer, as a first- or second-line chemotherapy regimen. Methods- S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest (1 cycle).
- Treatment was repeated until disease progression, unacceptable toxicity, or pt refusal.
Results- 45 pts were enrolled; among these, 29 pts received S-1 as first-line chemotherapy and 16 pts received S-1 as second-line chemotherapy.
- Response rates for first- and second-line chemotherapy were 17.2 and 18.8%, respectively.
- Median times to progression for first- and second-line chemotherapy groups were 4.2 and 5.5 mos, respectively.
- Median overall survival and 1-yr survival rate for each group were 8.7 and 8.0 mos and 42.2 and 38.2%, respectively.
- Only the first-line chemotherapy group experienced grade 3/4 toxicities, including leukopenia (6.9%), neutropenia (10.3%), anemia (6.9%), thrombocytopenia (10.3%) and total bilirubin elevation (3.4%).
[more...]
|
|
|
